文献速递卫生政策与健康促进免疫规划

发展中国家疫苗生产商的创新:优先排序、障碍与机遇

Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.
PubMed 文献 · Vaccine · 2021-01-22

该调查由发展中国家疫苗生产商网络与克林顿健康获取倡议合作开展,面向网络内企业成员,了解其对疫苗创新的态度、优先方向与障碍。结果显示95%受访者有创新意愿且策略面向中低收入国家供应,主要障碍包括引进许可或合资合作渠道、融资与监管方面。

要点

  • 95%受访发展中国家疫苗生产商对疫苗创新有兴趣。
  • 创新策略主要面向中低收入国家供应。
  • 主要障碍为许可引进或合资合作、融资与监管。

核心结论

  • 发展中国家疫苗生产商对疫苗创新有较强意愿,但面临合作、融资与监管等多重障碍。

研究设计与样本

  • 在发展中国家疫苗生产商网络成员企业中开展问卷调查,并与克林顿健康获取倡议合作完成。

主要发现

  • 95%受访者对开展疫苗创新有兴趣,创新策略针对中低收入国家供应。
  • 受访者指出的主要创新障碍包括获得许可引进或合资合作渠道、融资以及监管障碍。

临床怎么用

  • 可为公共卫生机构与生产商合作设计创新支持政策时提供障碍识别与优先方向参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of novel vaccines and improving existing vaccines is critical to addressing areas of unmet or under-addressed health needs globally and to improving existing vaccination coverage and equity. However, vaccine innovation is costly and highly complex. To understand how vaccine manufacturers from developing countries approach innovation, a survey was conducted among company members of the Developing Countries Vaccine Manufacturers Network, in collaboration with the Clinton Health Access Initiative. The survey confirmed that vaccine manufacturers from developing countries are committed to vaccine innovation: 95% of respondents have interest in pursuing vaccine innovation, with strategies targeted towards supplying to low- and middle-income countries. Key barriers to innovation were also surveyed, with respondents highlighting challenges regarding access to in-licensing or joint venture partnerships, financing, and regulatory barriers. Opportunities for innovation are also discussed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hayman B, Bowles A, Evans B, et al. Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities. Vaccine. 2021. PMID: 33487466. doi:10.1016/j.vaccine.2020.12.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。